-
Something wrong with this record ?
CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape
G. Hütter, J. Bodor, S. Ledger, M. Boyd, M. Millington, M. Tsie, G. Symonds,
Language English Country Switzerland
Document type Journal Article, Review
NLK
Directory of Open Access Journals
from 2009
Free Medical Journals
from 2009
PubMed Central
from 2009
Europe PubMed Central
from 2009
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2009-01-01
Health & Medicine (ProQuest)
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2009
PubMed
26225991
DOI
10.3390/v7082816
Knihovny.cz E-resources
- MeSH
- Biological Therapy methods MeSH
- Gene Knockdown Techniques MeSH
- HIV Infections therapy MeSH
- Humans MeSH
- Receptors, CCR5 genetics metabolism MeSH
- Receptors, HIV antagonists & inhibitors genetics metabolism MeSH
- Stem Cell Transplantation MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Allogeneic transplantation with CCR5-delta 32 (CCR5-d32) homozygous stem cells in an HIV infected individual in 2008, led to a sustained virus control and probably eradication of HIV. Since then there has been a high degree of interest to translate this approach to a wider population. There are two cellular ways to do this. The first one is to use a CCR5 negative cell source e.g., hematopoietic stem cells (HSC) to copy the initial finding. However, a recent case of a second allogeneic transplantation with CCR5-d32 homozygous stem cells suffered from viral escape of CXCR4 quasi-species. The second way is to knock down CCR5 expression by gene therapy. Currently, there are five promising techniques, three of which are presently being tested clinically. These techniques include zinc finger nucleases (ZFN), clustered regularly interspaced palindromic repeats/CRISPR-associated protein 9 nuclease (CRISPR/Cas9), transcription activator-like effectors nuclease (TALEN), short hairpin RNA (shRNA), and a ribozyme. While there are multiple gene therapy strategies being tested, in this review we reflect on our current knowledge of inhibition of CCR5 specifically and whether this approach allows for consequent viral escape.
Calimmune Inc Los Angeles CA 90024 USA
Cellex GmbH Fiedlerstr 36 01307 Dresden Germany
Faculty of Medicine University of New South Wales Sydney 2052 NSW Australia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16020462
- 003
- CZ-PrNML
- 005
- 20160801114650.0
- 007
- ta
- 008
- 160722s2015 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/v7082816 $2 doi
- 024 7_
- $a 10.3390/v7082816 $2 doi
- 035 __
- $a (PubMed)26225991
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Hütter, Gero $u Cellex GmbH, Fiedlerstr. 36, 01307 Dresden, Germany. g.huetter@cellex.me.
- 245 10
- $a CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape / $c G. Hütter, J. Bodor, S. Ledger, M. Boyd, M. Millington, M. Tsie, G. Symonds,
- 520 9_
- $a Allogeneic transplantation with CCR5-delta 32 (CCR5-d32) homozygous stem cells in an HIV infected individual in 2008, led to a sustained virus control and probably eradication of HIV. Since then there has been a high degree of interest to translate this approach to a wider population. There are two cellular ways to do this. The first one is to use a CCR5 negative cell source e.g., hematopoietic stem cells (HSC) to copy the initial finding. However, a recent case of a second allogeneic transplantation with CCR5-d32 homozygous stem cells suffered from viral escape of CXCR4 quasi-species. The second way is to knock down CCR5 expression by gene therapy. Currently, there are five promising techniques, three of which are presently being tested clinically. These techniques include zinc finger nucleases (ZFN), clustered regularly interspaced palindromic repeats/CRISPR-associated protein 9 nuclease (CRISPR/Cas9), transcription activator-like effectors nuclease (TALEN), short hairpin RNA (shRNA), and a ribozyme. While there are multiple gene therapy strategies being tested, in this review we reflect on our current knowledge of inhibition of CCR5 specifically and whether this approach allows for consequent viral escape.
- 650 _2
- $a biologická terapie $x metody $7 D001691
- 650 _2
- $a genový knockdown $7 D055785
- 650 _2
- $a HIV infekce $x terapie $7 D015658
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a receptory CCR5 $x genetika $x metabolismus $7 D019713
- 650 _2
- $a receptory HIV $x antagonisté a inhibitory $x genetika $x metabolismus $7 D015728
- 650 _2
- $a transplantace kmenových buněk $7 D033581
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Bodor, Josef $u Department of Cell Therapy, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic. bodor@uhkt.cz.
- 700 1_
- $a Ledger, Scott $u Faculty of Medicine, University of New South Wales, Sydney 2052 NSW, Australia. s.ledger@amr.org.au.
- 700 1_
- $a Boyd, Maureen $u Calimmune, Inc., Los Angeles, CA 90024, USA. maureen.boyd@calimmune.com.au.
- 700 1_
- $a Millington, Michelle $u Calimmune, Inc., Los Angeles, CA 90024, USA. michelle.millington@calimmune.com.au.
- 700 1_
- $a Tsie, Marlene $u Calimmune, Inc., Los Angeles, CA 90024, USA. marlene.tsie@calimmuneinc.com.
- 700 1_
- $a Symonds, Geoff $u Calimmune, Inc., Los Angeles, CA 90024, USA. geoff.symonds@calimmuneinc.com.
- 773 0_
- $w MED00177099 $t Viruses $x 1999-4915 $g Roč. 7, č. 8 (2015), s. 4186-203
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26225991 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20160801114917 $b ABA008
- 999 __
- $a ok $b bmc $g 1155132 $s 944990
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 7 $c 8 $d 4186-203 $e 20150727 $i 1999-4915 $m Viruses $n Viruses $x MED00177099
- LZP __
- $a Pubmed-20160722
